Top Story

Minimal immunosuppression recommended in transplant setting

April 20, 2017

AMSTERDAM — Understanding the impacts of fibrosis, drug–drug interactions with direct-acting antiviral therapies, and the pitfalls of immunosuppression can aid clinicians in treating liver transplantation candidates or recipients, according to data presented at the International Liver Congress.

Michael Charlton, MD, a transplant hepatologist and director of the Intermountain Transplant and Regenerative Medicine Center, said that the frequency of wait-listing for transplantation for patients with HCV has decreased considerably in recent years. “The indication is now highest for alcohol use,” he said. “The indications for NASH have remained relatively stable.”

In the Journals Plus

Most immune globulin products ineffective for hepatitis A prophylaxis

January 10, 2017
A recent letter published in JAMA Internal Medicine reports two of nine human immune globulin products tested for hepatitis A prophylaxis efficacy just meet the minimal
In the Journals

Permanent drug withdrawal observed in patients with autoimmune hepatitis

March 28, 2014
Permanent drug withdrawal was an achievable treatment-free outcome and varied widely for patients with autoimmune hepatitis, according to a meta-analysis. Researchers…
Industry News

Hepatology group urges UK’s health service to combat rise in liver disease

March 26, 2014
Members of the All-Party Parliamentary Hepatology Group have asked the National Health Service in the United Kingdom to show more concern about the rise of liver…
More Headlines »